How to book a medical appointment in Shanghai?

You can book through our online form, email, WeChat, or live chat. We will arrange the appointment within 24 hours and provide full assistance throughout your medical journey.

What languages do you support?

We provide full support in English, Russian, Chinese, Korean, and Japanese. All medical translations are handled by professional medical interpreters.

What are the payment methods?

Medical fees are paid directly to the hospital. Service fees can be paid via bank transfer, WeChat Pay, Alipay, or international wire transfer.

Do you help with visa arrangements?

Yes, we provide complete visa guidance and invitation letters for medical tourism to China.

Which hospitals do you partner with?

We partner with top-tier hospitals in Shanghai including Jiahui International Hospital, Huashan Hospital, Ruijin Hospital, and other leading medical institutions.

Lymphoma Treatment in Shanghai: 2026 International Patient Guide

Why Pathology Review Matters

Lymphoma is one of the most pathology-dependent cancers. Accurate subtype classification (DLBCL, follicular, mantle cell, marginal zone, NK/T, CNS lymphoma) determines the entire treatment strategy. FUSCC's pathology department led by Prof. Li Xiaoqiu (李小秋) is China's reference center for lymphoma pathology review.

Top Hospitals

FUSCC Pathology — Prof. Li Xiaoqiu, FISH for MYC/BCL2/BCL6, NGS genomic profiling.

FUSCC Medical Oncology — Prof. Zhao Weili (赵维莅, precision subtype-guided therapy, CAR-T); Prof. Cao Junning (曹军宁, 30+ years, BTK inhibitors, MDT); Prof. Tao Rong (陶蓉, NK/T, PTCL, high-risk DLBCL).

Ruijin Hospital — Prof. Zhao Weili also directs Shanghai Institute of Hematology; strong CAR-T program.

Huashan Hospital — Prof. Chen Tong (陈彤), novel therapies; Dr. Chen Bobin (陈伯斌) for CNS lymphoma.

Subtype-Specific Treatment

DLBCL: R-CHOP standard; high-risk double-hit/triple-hit receives dose-adjusted EPOCH-R or clinical trial; CAR-T (axicabtagene, relmacabtagene) for relapsed/refractory.

NK/T-cell (Asian-prevalent): Asparaginase-based regimens (DDGP, P-GemOx), PD-1 inhibitors; Prof. Tao Rong has Shanghai's deepest experience.

CNS lymphoma: Huashan's neurology/neurosurgery infrastructure combined with hematology; methotrexate-based regimens, ibrutinib.

Follicular/mantle cell: Chemoimmunotherapy, BTK inhibitors (zanubrutinib, orelabrutinib — Chinese-developed, more affordable).

CAR-T in Shanghai

Both FUSCC and Ruijin Hospital have CAR-T programs. Chinese domestic CAR-T products (relmacabtagene, equecabtagene) are significantly more affordable than imported axicabtagene, with comparable outcomes in DLBCL.

What to Bring

Unstained pathology slides + paraffin block (most important for re-review)

IHC reports and all stain results

FISH (MYC/BCL2/BCL6), NGS panel, TCR/BCR clonality

PET-CT (preferred) or CT chest/abdomen/pelvis

Brain MRI if CNS involvement suspected

Cost Reference

Standard R-CHOP: ¥30,000–60,000 per cycle. BTK inhibitors (zanubrutinib): ¥15,000–25,000/month. CAR-T (domestic): approximately ¥1,000,000–1,200,000 total; imported: ¥2,000,000+. Final costs depend on subtype and line of therapy.